Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial

Neuroinflammation through the cytokine, tumor necrosis factor-alpha (TNF-α) is thought to play an important role in the pathogenesis of amyotrophic lateral sclerosis (ALS). We conducted a preliminary phase II trial of thalidomide, which reduces levels of TNF-α pre-transcriptionally and post-transcri...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: STOMMEL, ELIJAH W., COHEN, JEFFREY A., FADUL, CAMILO E., COGBILL, CHRISTOPHER H., GRABER, DAVID J., KINGMAN, LINDA, MACKENZIE, TODD, SMITH, JACQUELINE Y. CHANNON, HARRIS, BRENT T.
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3820489/
https://ncbi.nlm.nih.gov/pubmed/19922130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/17482960802709416
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items